VISEN PHARMA-B (02561) surged over 12% again, rising 7.11% to HKD 35.26 by the time of writing, with a turnover of HKD 1.9082 million. On the news front, Anke Biotechnology recently disclosed progress in its collaboration with VISEN PHARMA-B, indicating that lonapegsomatropin, a long-acting growth hormone, is nearing approval. On July 14, Anke Biotechnology announced a strategic cooperation framework agreement with VISEN PHARMA-B to jointly promote lonapegsomatropin in the Chinese market. Notably, on November 6 during the 8th China International Import Expo, VISEN PHARMA-B entered into a strategic partnership with Tofflon Science and Technology Group Co., Ltd., a leading domestic pharmaceutical equipment manufacturer, for dual-chamber lyophilized formulation technology. Additionally, the company signed an industrial collaboration agreement with the Lingang New Area Administrative Committee and the Lingang Group's trade platform, marking further progress in its "Global Innovation, China Acceleration" strategy.